Guwahati Mail

Checkpoint Inhibitors Pipeline Drugs Analysis Report (2023 Updates) : FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Checkpoint Inhibitors Pipeline Drugs Analysis Report (2023 Updates) : FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 11
19:06 2023
Checkpoint Inhibitors Pipeline Drugs Analysis Report (2023 Updates) : FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Checkpoint Inhibitors Pipeline

(Albany, USA) DelveInsight’s ‘Checkpoint Inhibitors Competitive Landscape – 2023’ report provides comprehensive global coverage of available, marketed, and pipeline checkpoint inhibitor drugs in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the checkpoint inhibitors competitive domain.

 

Request for free sample page @ Checkpoint Inhibitors Competitive Landscape

 

Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report

  • Over 180+ checkpoint inhibitors companies are evaluating 250+ checkpoint inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the checkpoint inhibitors market would significantly increase market revenue. 
  • Leading checkpoint inhibitor companies such as BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine,Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, Alpine Immune Sciences, Arcus Biosciences, Elpiscience Biopharmaceuticals, TransCode Therapeutics, Checkpoint Therapeutics, Orum Therapeutics, Avacta, Exelixis, and others are evaluating novel Checkpoint inhibitor drugs candidate to improve the treatment landscape.
  • Key checkpoint inhibitor pipeline therapies in various stages of development include BCD-100, CBP501, BEBT-260, FAZ053, Envafolimab, SG 12473, HBM-9027, CA-170, Tislelizumab, Geptanolimab, BCN 176, PH-3861, Adebrelimab, M7824, IBI-310, AGEN-1181, YH-001, PEP07,  V-158411, Prexasertib, GDC-0575, PH-762, BI 765063, SOL-578, SRA 737, IMP 10, VER250840, ALPN-202, Zimberelimab,  ES101, ES019, TTX siPDL1, Cosibelimab,  Research programme: PD-1-Cbl-b therapeutics, APL 502, APL-801, AVA 028, AVA 021,  LR-19128 PD-L1 XT, XB-628, XB014, SHR 1701 and others.
  • In April 2023, Enlivex Therapeutics Ltd. announced a clinical collaboration agreement with BeiGene. The Company entered into this collaboration to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company’s ongoing Phase I/II clinical trial.

 

Request a sample and discover the recent advances in the checkpoint inhibitors market @ Checkpoint Inhibitors Competitive Landscape Report

 

Checkpoint Inhibitors Overview

Checkpoint inhibitors are a type of immunotherapy. They obstruct proteins that prevent the immune system from attacking cancer cells. Cancer medications do not usually fit neatly into a specific form of treatment, and this is because certain medications function in multiple methods and belong to more than one class. Checkpoint inhibitors are frequently referred to as monoclonal antibodies or targeted treatments. The immune system protects humans from disease by killing germs and viruses, and t cells are the most common type of immune cell that achieves this.

Checkpoint inhibitors are drugs that suppress checkpoint proteins. They prevent proteins in cancer cells from pressing the stop button, and this activates the immune system, allowing T cells to locate and attack cancer cells. These medications inhibit the following checkpoint proteins: CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed cell death ligand 1). T cells express CTLA-4 and PD-1, and PD-L1 is found in cancer cells. These medications stimulate all immune cells, not just those that fight cancer. As a result, hyperactive T cells may have unintended consequences. 

 

Find out more about FDA checkpoint inhibitors @ Checkpoint Inhibitor Drugs

 

Checkpoint Inhibitors Pipeline Analysis: Drug Profile

BCD-100: BIOCAD

Prolgolimab (BCD-100), developed by BIOCAD, is a completely human monoclonal antibody with PD-1 receptor specificity. It is an immunoglobulin G1 with L234A/L235A mutations that result in reduced affinity for Fc receptors. It is Eastern Europe’s first immune checkpoint inhibitor. In Russia, prolgolimab is already approved for the treatment of unresectable or metastatic melanoma. Prolgolimab is also being developed in combination with other medicines for the treatment of advanced NSCLC and cervical cancer as part of the Harmony clinical program. The drug is currently in Phase III development for the treatment of Non-Squamous Non-Small Cell Lung Neoplasm.

CBP501: CanBas Co., Ltd.

CanBas’s CBP501 is a novel calmodulin-modulating peptide with a well-defined multimodal anti-tumor function. This mode of action leads to increased platinum influx into and cytotoxicity to tumor cells, specifically, immunogenic cell death of tumor cells, suppression of M2 macrophage activity, reduced populations of cancer stem cells, and reduced migration/invasion by and epithelial-to-mesenchymal transition (EMT) of tumor cells even with short-term exposure treatment. CBP501 also improves the efficacy of some immune checkpoint inhibitors when combined with cisplatin or carboplatin. In the CT-26 syngeneic mice model, CBP501 and a platinum drug combined with anti-PD1, anti-PDL1, or anti-CTLA4 inhibit tumor growth while increasing CD8 T cells and decreasing M2 macrophages at tumor locations. The drug is currently in a Phase II clinical trial for the treatment of Stage IV pancreatic cancer.

 

Checkpoint Inhibitors Pipeline Drugs:

  • BCD-100: BIOCAD
  • Envafolimab: 3D Medicines
  • IBI310: Innovent Biologics
  • Bintrafusp alfa: EMD Serono/Merck
  • CA-170: Aurigene Discovery Technologies
  • CBP501: CanBas Co., Ltd.
  • Botensilimab: Agenus
  • FAZ053: Laekna Therapeutics
  • BEBT-260: BeBetter Med
  • SG 12473: Hangzhou Sumgen Biotech
  • HBM-9027: Harbour BioMed
  • PH-3861: Phio Pharmaceuticals

 

Learn more about the checkpoint inhibitor drugs @ Checkpoint Inhibitor Clinical Trials

 

Scope of the Checkpoint Inhibitors Competitive Landscape Report 

  • Coverage: Global 
  • Key Checkpoint Inhibitors Companies: BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine,Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, Alpine Immune Sciences, Arcus Biosciences, Elpiscience Biopharmaceuticals, and others
  • Key Checkpoint Inhibitors Pipeline Therapies: BCD-100, CBP501, BEBT-260, FAZ053, Envafolimab, SG 12473, HBM-9027, CA-170, Tislelizumab, Geptanolimab, BCN 176, PH-3861, Adebrelimab, M7824, IBI-310, AGEN-1181, YH-001, PEP07,  V-158411, Prexasertib, GDC-0575, PH-762, BI 765063, SOL-578, SRA 737, IMP 10, VER250840, ALPN-202, Zimberelimab,  ES101, ES019, and others.
  • Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive drugs assessment, Unmet Needs

 

Dive deep for rich insights into checkpoint inhibitor therapy; visit @ FDA-approved Checkpoint Inhibitors 

 

Table of Contents

1.

Checkpoint Inhibitors Pipeline Report Introduction

2.

Checkpoint Inhibitors Pipeline Report Executive Summary

3.

Checkpoint Inhibitors Pipeline: Overview

4.

Marketed Checkpoint Inhibitors Drugs

4.1. 

Pembrolizumab: Merck

5.

Checkpoint Inhibitors Clinical Trial Therapeutics

6.

Checkpoint Inhibitors Pipeline: Late-Stage Products (Pre-registration)

7.

Checkpoint Inhibitors Pipeline: Late-Stage Products (Phase III)

7.1.

BCD-100: BIOCAD

8.

Checkpoint Inhibitors Pipeline: Mid-Stage Products (Phase II)

8.1.

CBP501: CanBas Co., Ltd.

9.

Checkpoint Inhibitors Pipeline: Early-Stage Products (Phase I)

9.1.

BEBT-260: BeBetter Med

10.

Checkpoint Inhibitors Pipeline Therapeutic Assessment

11.

Inactive Products in the Checkpoint Inhibitors Pipeline

12.

Company-University Collaborations (Licensing/Partnering) Analysis

13.

Unmet Needs

14.

Market Drivers and Barriers

15.

Appendix

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Categories